BR112014018106A2 - composto, uso de um composto, e, método para tratar uma doença fibrótica - Google Patents
composto, uso de um composto, e, método para tratar uma doença fibróticaInfo
- Publication number
- BR112014018106A2 BR112014018106A2 BR112014018106A BR112014018106A BR112014018106A2 BR 112014018106 A2 BR112014018106 A2 BR 112014018106A2 BR 112014018106 A BR112014018106 A BR 112014018106A BR 112014018106 A BR112014018106 A BR 112014018106A BR 112014018106 A2 BR112014018106 A2 BR 112014018106A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- fibrotic disease
- treating fibrotic
- treating
- fibrotic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595293P | 2012-02-06 | 2012-02-06 | |
| US201261702854P | 2012-09-19 | 2012-09-19 | |
| PCT/EP2013/052112 WO2013117503A2 (en) | 2012-02-06 | 2013-02-04 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014018106A2 true BR112014018106A2 (pt) | 2017-06-27 |
Family
ID=47633093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014018106A BR112014018106A2 (pt) | 2012-02-06 | 2013-02-04 | composto, uso de um composto, e, método para tratar uma doença fibrótica |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150051215A1 (https=) |
| EP (1) | EP2812002A2 (https=) |
| JP (1) | JP2015509483A (https=) |
| KR (1) | KR20140127307A (https=) |
| CN (1) | CN104093408A (https=) |
| AU (1) | AU2013218148A1 (https=) |
| BR (1) | BR112014018106A2 (https=) |
| CA (1) | CA2861521A1 (https=) |
| RU (1) | RU2014128387A (https=) |
| WO (1) | WO2013117503A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| CA3017028C (en) | 2015-07-30 | 2020-06-16 | Monash University | Fibrotic treatment |
| JP6419097B2 (ja) * | 2016-01-14 | 2018-11-07 | 学校法人東京農業大学 | ヤマノイモ属植物からのディオスコリンの製造方法 |
| WO2018177301A1 (zh) | 2017-04-01 | 2018-10-04 | 郑州大学 | 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
-
2013
- 2013-02-04 JP JP2014555239A patent/JP2015509483A/ja active Pending
- 2013-02-04 KR KR20147024991A patent/KR20140127307A/ko not_active Withdrawn
- 2013-02-04 BR BR112014018106A patent/BR112014018106A2/pt not_active IP Right Cessation
- 2013-02-04 US US14/376,664 patent/US20150051215A1/en not_active Abandoned
- 2013-02-04 EP EP13702473.3A patent/EP2812002A2/en not_active Withdrawn
- 2013-02-04 AU AU2013218148A patent/AU2013218148A1/en not_active Abandoned
- 2013-02-04 CA CA2861521A patent/CA2861521A1/en not_active Abandoned
- 2013-02-04 RU RU2014128387A patent/RU2014128387A/ru unknown
- 2013-02-04 CN CN201380008089.XA patent/CN104093408A/zh active Pending
- 2013-02-04 WO PCT/EP2013/052112 patent/WO2013117503A2/en not_active Ceased
-
2015
- 2015-11-18 US US14/944,531 patent/US20160067247A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015509483A (ja) | 2015-03-30 |
| KR20140127307A (ko) | 2014-11-03 |
| EP2812002A2 (en) | 2014-12-17 |
| CA2861521A1 (en) | 2013-08-15 |
| WO2013117503A3 (en) | 2013-10-03 |
| WO2013117503A2 (en) | 2013-08-15 |
| US20150051215A1 (en) | 2015-02-19 |
| AU2013218148A1 (en) | 2014-07-24 |
| CN104093408A (zh) | 2014-10-08 |
| US20160067247A1 (en) | 2016-03-10 |
| RU2014128387A (ru) | 2016-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| UY34474A (es) | Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C. | |
| BR112015008987A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica | |
| CY1119170T1 (el) | Ενωση γουανιδινης | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| BR112015009216A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica | |
| JOP20120246B1 (ar) | مركبات و تركيبات كمثبطات كيناز c-Kit | |
| IN2014DN09434A (https=) | ||
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| BR112014018106A2 (pt) | composto, uso de um composto, e, método para tratar uma doença fibrótica | |
| EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| EA201290860A1 (ru) | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата | |
| MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| EA201591628A1 (ru) | Дейтерированный палбоциклиб | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |